Cost of Revenue Comparison: Eli Lilly and Company vs Corcept Therapeutics Incorporated

Cost of Revenue: A Tale of Two Companies

In the competitive landscape of pharmaceuticals, understanding cost structures is crucial. Eli Lilly and Company, a stalwart in the industry, has consistently maintained a high cost of revenue, averaging around $5.76 billion annually from 2014 to 2023. In contrast, Corcept Therapeutics Incorporated, a smaller player, has seen its cost of revenue grow from $882,000 in 2014 to $6.48 million in 2023, marking a staggering increase of over 600%.

A Decade of Growth and Challenges

While Eli Lilly's cost of revenue fluctuated, peaking at $7.31 billion in 2021, Corcept's steady rise reflects its expanding operations and market presence. This comparison highlights the diverse strategies and challenges faced by pharmaceutical companies in managing production costs over the past decade. As the industry evolves, these insights offer a glimpse into the financial dynamics shaping the future of healthcare.